Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Substance Abuse Treatment, Prevention, and Policy
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2014

Open Access 01-12-2014 | Research

Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance

Authors: Ute Maurer, Carola Kager, Christina Fellinger, Dagmara Loader, Augustin Pollesböck, Bernhard Spitzer, Reinhart Jarisch

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2014

Login to get access

Abstract

Background

Across Europe, illicit drug-related mortality has not declined despite ever increasing prevention measures. The cause of these deaths has traditionally been associated with overdose. Previous findings have revealed the appearance of non-lethal opioid concentrations, leading us to investigate a further cause of death. The symptoms of heroin intoxication with asphyxia and/or cardiovascular involvement resemble anaphylaxis, and therefore it has been speculated that such deaths might be caused by an allergic reaction. The study´s aims were to investigate levels of allergic mediators in long-term injecting drug users (IDU) compared to healthy controls and to determine if oral opioid substitution therapy (OST) resulted in similar allergic symptoms to those reported by IDU after intravenous (IV) heroin use.

Methods

We quantified the concentrations of histamine, diamine oxidase (DAO), tryptase and lipoprotein-associated phospholipase A2 (LpPLA2) at baseline and 1 h after administration of Substitol®retard (482 ± 220 mg) in 56 patients at a withdrawal centre (Austria) and compared them with healthy controls (n = 103). Questionnaires and face-to-face interviews were used to assess allergic symptoms and side effects in IDU. Descriptive statistical analyses of quantitative data were performed by using SPSS.

Results

Baseline histamine, tryptase and LpPLA2 were significantly elevated in IDU compared to the healthy control group, while DAO decreased. Blood levels showed no significant change after oral substitution uptake. Self-reported allergic symptoms and side effects after IV heroin use were reported in 55 cases (98.2%), minimal symptoms were documented after OST (12.5%, 7/56).

Conclusions

This study revealed that baseline histamine concentrations were elevated in chronic IDU, although only relatively small changes in tryptase plasma levels occurred. After IV heroin application the reported allergic symptoms were mostly mild and did not lead to clinically relevant side effects. The substitution substance was clearly better tolerated than IV administered heroin. Elevated levels of allergic mediators such as histamine in IDUs may place them at greater risk of severe or fatal anaphylaxis when exposed to heroin; however, this requires further investigation.
Appendix
Available only for authorised users
Literature
1.
Risser D, Honigschnabl S, Stichenwirth M, Pfudl S, Sebald D, Kaff A, Bauer G: Mortality of opiate users in Vienna, Austria. Drug Alcohol Depend. 2001, 64 (3): 251-256. 10.1016/S0376-8716(01)00131-4.CrossRefPubMed
2.
Risser D, Schneider B: Drug-related deaths between 1985 and 1992 examined at the Institute of Forensic Medicine in Vienna, Austria. Addiction. 1994, 89 (7): 851-857. 10.1111/j.1360-0443.1994.tb00988.x.CrossRefPubMed
3.
Darke S, Zador D: Fatal heroin 'overdose': a review. Addiction. 1996, 91 (12): 1765-1772. 10.1111/j.1360-0443.1996.tb03800.x.CrossRefPubMed
4.
Staub C, Jeanmonod R, Fryc O: Morphine in postmortem blood: its importance for the diagnosis of deaths associated with opiate addiction. Int J Legal Med. 1990, 104 (1): 39-42. 10.1007/BF01816482.CrossRefPubMed
5.
Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M: Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013, 91 (2): 102-123. 10.2471/BLT.12.108282.PubMedCentralCrossRefPubMed
6.
Polettini A, Poloni V, Groppi A, Stramesi C, Vignali C, Politi L, Montagna M: The role of cocaine in heroin-related deaths. Hypothesis on the interaction between heroin and cocaine. Forensic Sci Int. 2005, 153 (1): 23-28. 10.1016/j.forsciint.2005.04.017.CrossRefPubMed
7.
8.
9.
Simons FE: World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Ann Allergy Asthma Immunol. 2010, 104 (5): 405-412. 10.1016/j.anai.2010.01.023.CrossRefPubMed
10.
Ben-Shoshan M, Clarke AE: Anaphylaxis: past, present and future. Allergy. 2011, 66 (1): 1-14. 10.1111/j.1398-9995.2010.02422.x.CrossRefPubMed
11.
Pumphrey R: Anaphylaxis: can we tell who is at risk of a fatal reaction?. Curr Opin Allergy Clin Immunol. 2004, 4 (4): 285-290. 10.1097/01.all.0000136762.89313.0b.CrossRefPubMed
12.
Tsai MG, S. G : Mast cells: effector cells of anaphylaxis. Anaphylaxis and Hypersensitivity Reactions. Edited by: Castells MC. 2011, New York: Humana Press, 47-68.CrossRef
13.
Lee JK, Vadas P: Anaphylaxis: mechanisms and management. Clin Exp Allergy. 2011, 41 (7): 923-938. 10.1111/j.1365-2222.2011.03779.x.CrossRefPubMed
14.
Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG: Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol. 2009, 124 (4): 786-792. 10.1016/j.jaci.2009.07.055. e784CrossRefPubMed
15.
16.
Schwartz LB: Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp. 2004, 257: 65-74. discussion 74-69, 98-100, 276-185CrossRefPubMed
17.
Simons FE, Sampson HA: Anaphylaxis epidemic: fact or fiction?. J Allergy Clin Immunol. 2008, 122 (6): 1166-1168. 10.1016/j.jaci.2008.10.019.CrossRefPubMed
18.
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, Brown SG, Camargo CA, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006, 117 (2): 391-397. 10.1016/j.jaci.2005.12.1303.CrossRefPubMed
19.
Sanz ML, Gamboa PM, Garcia-Figueroa BE, Ferrer M: In vitro Diagnosis of Anaphylaxis. Anaphylaxis Chemical Immunology and Allergy, Volume 95. Edited by: Ring J. 2010, Basel: Kager, 125-140.
20.
Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989, 83 (5): 1551-1555. 10.1172/JCI114051.PubMedCentralCrossRefPubMed
21.
Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006, 26 (3): 451-463. 10.1016/j.iac.2006.05.010.CrossRefPubMed
22.
Baldo BA, Pham NH: Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care. 2012, 40 (2): 216-235.PubMed
23.
Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH: Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology. 2000, 92 (4): 1074-1081. 10.1097/00000542-200004000-00026.CrossRefPubMed
24.
Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology. 1992, 77 (5): 932-940. 10.1097/00000542-199211000-00016.CrossRefPubMed
25.
Organization WH: ICD-10, the ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. 1993, World Health Organization
26.
Union E: EU Drugs Strategy (2013-2020). 2012
27.
28.
29.
Di Bello MG, Masini E, Ioannides C, Ndisang JF, Raspanti S, Bani Sacchi T, Mannaioni PF: Histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals. Inflamm Res. 1998, 47 (3): 122-130. 10.1007/s000110050299.CrossRefPubMed
30.
Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA: Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology. 1985, 62 (2): 124-129. 10.1097/00000542-198502000-00005.CrossRefPubMed
31.
Immunotech BCC: RIA Histamine, Immunradiometrischer Assay für die quantitative in vitro Bestimmung von Histamin in biologischen Proben. Immunotech SAS, 1-18.
32.
Jarisch R: Histamin-Intoleranz, Histamin und Seekrankheit. 2013, Stuttgart: Thieme Verlag
33.
Luk GD, Bayless TM, Baylin SB: Diamine oxidase (histaminase): a circulating marker for rat intestinal mucosal maturation and integrity. J Clin Invest. 1980, 66 (1): 66-70. 10.1172/JCI109836.PubMedCentralCrossRefPubMed
34.
Raithel M, Ulrich P, Hochberger J, Hahn EG: Measurement of gut diamine oxidase activity. Diamine oxidase as a new biologic marker of colorectal proliferation?. Ann N Y Acad Sci. 1998, 859: 262-266. 10.1111/j.1749-6632.1998.tb11142.x.CrossRefPubMed
35.
Mayer DE, Krauskopf A, Hemmer W, Moritz K, Jarisch R, Reiter C: Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci Int. 2011, 212 (1–3): 96-101.CrossRefPubMed
36.
37.
Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987, 316 (26): 1622-1626. 10.1056/NEJM198706253162603.CrossRefPubMed
38.
Payne V, Kam PC: Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004, 59 (7): 695-703. 10.1111/j.1365-2044.2004.03757.x.CrossRefPubMed
39.
40.
Dada N, Kim NW, Wolfert RL: Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002, 2 (1): 17-22. 10.1586/14737159.2.1.17.CrossRefPubMed
41.
Carlquist JF, Muhlestein JB, Anderson JL: Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007, 7 (5): 511-517. 10.1586/14737159.7.5.511.CrossRefPubMed
42.
Zalewski A, Nelson JJ, Hegg L, Macphee C: Lp-PLA2: a new kid on the block. Clin Chem. 2006, 52 (9): 1645-1650. 10.1373/clinchem.2006.070672.CrossRefPubMed
43.
44.
Hirshman CA, Downes H, Butler S: Relevance of plasma histamine levels to hypotension. Anesthesiology. 1982, 57 (5): 424-426. 10.1097/00000542-198211000-00018.CrossRefPubMed
45.
Fahmy NR, Sunder N, Soter NA: Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther. 1983, 33 (5): 615-620. 10.1038/clpt.1983.83.CrossRefPubMed
46.
Barke KE, Hough LB: Opiates, mast cells and histamine release. Life Sci. 1993, 53 (18): 1391-1399. 10.1016/0024-3205(93)90581-M.CrossRefPubMed
47.
Marone G, Stellato C, Mastronardi P, Mazzarella B: Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Annales francaises d'anesthesie et de reanimation. 1993, 12 (2): 116-125. 10.1016/S0750-7658(05)81020-2.CrossRefPubMed
48.
Levy JH, Brister NW, Shearin A, Ziegler J, Hug CC, Adelson DM, Walker BF: Wheal and flare responses to opioids in humans. Anesthesiology. 1989, 70 (5): 756-760. 10.1097/00000542-198905000-00008.CrossRefPubMed
49.
Leysen J, De Witte L, Sabato V, Faber M, Hagendorens M, Bridts C, De Clerck L, Ebo D: IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: Lessons from flow cytometry. Cytometry B Clin Cytom. 2013, 84 (2): 65-70.CrossRefPubMed
50.
Edston E, van Hage-Hamsten M: beta-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int. 1998, 93 (2-3): 135-142. 10.1016/S0379-0738(98)00040-1.CrossRefPubMed
51.
Edston E, van Hage-Hamsten M: Anaphylactoid shock–a common cause of death in heroin addicts?. Allergy. 1997, 52 (9): 950-954. 10.1111/j.1398-9995.1997.tb01256.x.CrossRefPubMed
52.
Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH: The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005, 824 (1–2): 213-221.CrossRefPubMed
53.
Karasuyama H, Mukai K, Tsujimura Y, Obata K: Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol. 2009, 9 (1): 9-13. 10.1038/nri2458.CrossRefPubMed
54.
Mukai K, Obata K, Tsujimura Y, Karasuyama H: [The roles for basophils in allergy]. Nihon Rinsho. 2009, 67 (11): 2095-2099.PubMed
55.
Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, Maerz W, Brenner H, Koenig W: Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005, 182 (1): 181-188. 10.1016/j.atherosclerosis.2004.10.046.CrossRefPubMed
56.
Haemmig RB, Tschacher W: Effects of high-dose heroin versus morphine in intravenous drug users: a randomised double-blind crossover study. J Psychoactive Drugs. 2001, 33 (2): 105-110. 10.1080/02791072.2001.10400475.CrossRefPubMed
57.
Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB: Morphine-induced venodilation in humans. Clin Pharmacol Ther. 1996, 60 (5): 554-560. 10.1016/S0009-9236(96)90151-4.CrossRefPubMed
58.
Schug SA, Zech D, Grond S: Adverse effects of systemic opioid analgesics. Drug Saf. 1992, 7 (3): 200-213. 10.2165/00002018-199207030-00005.CrossRefPubMed
59.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011, 378 (9791): 571-583. 10.1016/S0140-6736(11)61097-0.PubMedCentralCrossRefPubMed
60.
Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P: Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol. 1993, 22 (2): 315-320. 10.1093/ije/22.2.315.CrossRefPubMed
Metadata
Title
Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance
Authors
Ute Maurer
Carola Kager
Christina Fellinger
Dagmara Loader
Augustin Pollesböck
Bernhard Spitzer
Reinhart Jarisch
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2014
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/1747-597X-9-12

Other articles of this Issue 1/2014

Substance Abuse Treatment, Prevention, and Policy 1/2014 Go to the issue

Research

Perceived neighborhood illicit drug selling, peer illicit drug disapproval and illicit drug use among U.S. high school seniors

Research

Groin injecting among a community-recruited sample of people who inject drugs in Thailand

Research

Substance use disorders in Arab countries: research activity and bibliometric analysis

Research

A qualitative exploration of attitudes towards alcohol, and the role of parents and peers of two alcohol-attitude-based segments of the adolescent population

Research

The national alcohol helpline in Sweden: an evaluation of its first year

Review

The aetiology and trajectory of anabolic-androgenic steroid use initiation: a systematic review and synthesis of qualitative research